A clinical Escherichia coli isolate resistant to all -lactams, including carbapenems, expressed a novel metallo--lactamase (MBL), NDM-4, differing from NDM-1 by a single amino acid substitution (Met154Leu). NDM-4 possessed increased hydrolytic activity toward carbapenems and several cephalosporins compared to that of NDM-1. This amino acid substitution was not located in the known active sites of NDM-1, indicating that remote amino acid substitutions might also play a role in the extended activity of this MBL.A cquired metallo--lactamases (MBLs) are emerging resistance determinants in clinically relevant Gram-negative species (19). NDM-1 (New Delhi metallo--lactamase 1) has been recently identified, being first described from Klebsiella pneumoniae and Escherichia coli isolated in Sweden in 2008 from an Indian patient (23). NDM-1, as is the case for any MBL, confers a broad-spectrum -lactam resistance, hydrolyzing penicillins, cephalosporins, and carbapenems but sparing monobactams (23). The rapid and large dissemination of NDM-1-producing Gram-negative species has been emphasized in many reports that have been published in the last 2 years (13,16,20). In Enterobacteriaceae, the bla NDM-1 gene has been shown to be carried by different plasmid types (IncA/C, IncF, IncL/M, or untypeable) (13,16,17). Most bla NDM-1 -encoding plasmids coharbored multiple and variable resistance determinants, including those for -lactams, quinolones, aminoglycosides, rifampin, chloramphenicol, and macrolides (13,16,17). The bla NDM-1 gene has been widely identified in Enterobacteriaceae but also in Acinetobacter baumannii from Germany, India, the United Kingdom, and China (4, 5, 10, 11). In addition, NDM-2-producing A. baumannii isolates have been reported from Egypt and Israel (7, 10). NDM-2 differs from NDM-1 by a single amino acid substitution (Pro28Ala) located in the leader peptide of the enzyme that does not modify its hydrolytic properties compared to those of NDM-1 (7, 21). We report here the identification of a novel NDM variant that possesses extended hydrolytic properties.E. coli I5 was recovered from a urinary culture of a patient hospitalized in India in January 2010. Susceptibility testing was performed by disk diffusion assay (Sanofi-Diagnostic Pasteur, Marnes-la-Coquette, France) as previously described (6a). Results were interpreted according to the CLSI guidelines (6a). The MICs were determined by Etest (AB bioMérieux, Solna, Sweden) on Mueller-Hinton agar plates at 37°C. E. coli I5 was resistant to all -lactams, including imipenem, meropenem, and ertapenem (Table 1). This isolate was additionally resistant to all tested aminoglycosides and fluoroquinolones. Production of MBL was assessed using Etest MBL (AB bioMérieux, Solna Sweden), which gave a positive result. Whole-cell DNA of E. coli isolate I5 was extracted using a QiaAmp minikit according to manufacturer recommendations (Qiagen, Courtaboeuf, France), and DNA was used as a template for the detection of different -lactamases and 16S rRNA methylase genes...